David Nierengarten
Stock Analyst at Wedbush
(4.25)
# 425
Out of 5,140 analysts
216
Total ratings
51.98%
Success rate
15.62%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COGT Cogent Biosciences | Reiterates: Outperform | $55 | $39.90 | +37.84% | 4 | Jan 21, 2026 | |
| IMNM Immunome | Reiterates: Outperform | $31 | $24.87 | +24.65% | 7 | Jan 15, 2026 | |
| NVCR NovoCure | Reiterates: Neutral | $18 | $13.56 | +32.74% | 9 | Jan 15, 2026 | |
| ARGX argenx SE | Reiterates: Outperform | $1,000 | $816.37 | +22.49% | 24 | Jan 14, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $48 → $50 | $41.83 | +19.53% | 5 | Jan 13, 2026 | |
| BCAX Bicara Therapeutics | Reiterates: Outperform | $30 | $16.97 | +76.78% | 3 | Jan 13, 2026 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $20 | $12.25 | +63.27% | 9 | Jan 13, 2026 | |
| GBIO Generation Bio Co. | Upgrades: Outperform | $7 → $5.5 | $5.46 | +0.73% | 10 | Dec 16, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Reiterates: Outperform | $25 | $11.39 | +119.49% | 3 | Dec 11, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $9 → $7 | $14.03 | -50.11% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $5 → $7 | $1.18 | +493.22% | 16 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $110 | $74.89 | +46.88% | 4 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $6.15 | -2.44% | 11 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $115 | $109.04 | +5.47% | 6 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $4 | $4.44 | -9.91% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $13.00 | +100.00% | 8 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $7.31 | +200.96% | 3 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $18.08 | -55.75% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $2.55 | +331.37% | 4 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $20 | $15.80 | +26.58% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $46.68 | -14.31% | 13 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $87 → $90 | $81.91 | +9.88% | 3 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $46.05 | +2.06% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $34.46 | +16.08% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $33.99 | +32.39% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.14 | +777.19% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $4.75 | +278.95% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $4.01 | +199.25% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $31.12 | +83.16% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $2.90 | +17,141.38% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $6.32 | +849.37% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $7.70 | +146.75% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $22.75 | +229.67% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.24 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.77 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.68 | - | 3 | Nov 20, 2017 |
Cogent Biosciences
Jan 21, 2026
Reiterates: Outperform
Price Target: $55
Current: $39.90
Upside: +37.84%
Immunome
Jan 15, 2026
Reiterates: Outperform
Price Target: $31
Current: $24.87
Upside: +24.65%
NovoCure
Jan 15, 2026
Reiterates: Neutral
Price Target: $18
Current: $13.56
Upside: +32.74%
argenx SE
Jan 14, 2026
Reiterates: Outperform
Price Target: $1,000
Current: $816.37
Upside: +22.49%
Kiniksa Pharmaceuticals International,
Jan 13, 2026
Maintains: Outperform
Price Target: $48 → $50
Current: $41.83
Upside: +19.53%
Bicara Therapeutics
Jan 13, 2026
Reiterates: Outperform
Price Target: $30
Current: $16.97
Upside: +76.78%
ORIC Pharmaceuticals
Jan 13, 2026
Reiterates: Outperform
Price Target: $20
Current: $12.25
Upside: +63.27%
Generation Bio Co.
Dec 16, 2025
Upgrades: Outperform
Price Target: $7 → $5.5
Current: $5.46
Upside: +0.73%
BridgeBio Oncology Therapeutics
Dec 11, 2025
Reiterates: Outperform
Price Target: $25
Current: $11.39
Upside: +119.49%
Intellia Therapeutics
Nov 7, 2025
Maintains: Neutral
Price Target: $9 → $7
Current: $14.03
Upside: -50.11%
Oct 27, 2025
Upgrades: Outperform
Price Target: $5 → $7
Current: $1.18
Upside: +493.22%
Oct 17, 2025
Maintains: Outperform
Price Target: $90 → $110
Current: $74.89
Upside: +46.88%
Oct 13, 2025
Reiterates: Outperform
Price Target: $6
Current: $6.15
Upside: -2.44%
Sep 8, 2025
Reiterates: Outperform
Price Target: $115
Current: $109.04
Upside: +5.47%
Sep 8, 2025
Initiates: Outperform
Price Target: $4
Current: $4.44
Upside: -9.91%
Sep 2, 2025
Reiterates: Outperform
Price Target: $26
Current: $13.00
Upside: +100.00%
Aug 28, 2025
Reiterates: Outperform
Price Target: $22
Current: $7.31
Upside: +200.96%
Jun 26, 2025
Reiterates: Neutral
Price Target: $8
Current: $18.08
Upside: -55.75%
Jun 23, 2025
Reiterates: Outperform
Price Target: $11
Current: $2.55
Upside: +331.37%
Mar 14, 2025
Downgrades: Neutral
Price Target: $80 → $20
Current: $15.80
Upside: +26.58%
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $46.68
Upside: -14.31%
Dec 2, 2024
Maintains: Outperform
Price Target: $87 → $90
Current: $81.91
Upside: +9.88%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $46.05
Upside: +2.06%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $34.46
Upside: +16.08%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $33.99
Upside: +32.39%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.14
Upside: +777.19%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $4.75
Upside: +278.95%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $4.01
Upside: +199.25%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $31.12
Upside: +83.16%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $2.90
Upside: +17,141.38%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $6.32
Upside: +849.37%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $7.70
Upside: +146.75%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $22.75
Upside: +229.67%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.24
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $3.77
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $9.68
Upside: -